Equillium Inc. (EQ)
NASDAQ: EQHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
EQ stock chart
Technical analysisKey statistics
All statistics- Market cap
- $91.31M
- EPS (TTM)
- -$0.14
- Dividend yield
- None
- 52-week range
- 0.76 – 3.54
- Day range
- 1.34 – 1.46
- Volume / Avg
- 645.03K / 583.72K
- Beta
- —
- Shares outstanding
- 63.41M
- Next earnings
- Nov 12, 2026
52-week range
EQ stock today
Shares of Equillium (EQ) finished higher on Oct 8 at $1.44, a gain of 3.60% or $0.05 per share, versus the S&P 500's 0.47% decline. At this level, EQ sits in the middle of its 52-week range of $0.76 to $3.54: 59.3% below the high, set on Jun 30, 2026 and 89.5% above the low. EQ is down 7.1% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 2.0%.
Equillium has posted a net loss over the last twelve months (EPS of -$0.14), so its P/E ratio is not meaningful. Equillium's next earnings report is expected on Nov 12, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Equillium
Company profileEquillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Bruce Steel
- Headquarters
- La Jolla, CA
- Employees
- 14
- IPO year
- 2018
- Website
- equilliumbio.com
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$8.56+494.44%
- Strong buy 1
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 12, 2026
Equillium peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RLYBRallybio Corporation | 16.99 | +0.35% | $90.26M | vs EQ |
| NMRANeumora Therapeutics Inc. | 0.4798 | +2.46% | $90.15M | vs EQ |
| ATRAAtara Biotherapeutics Inc. | 9.23 | -1.49% | $92.65M | vs EQ |
| OKUROnKure Therapeutics Inc. Class A | 2.30 | -2.13% | $93.14M | vs EQ |
| MISTMilestone Pharmaceuticals Inc. | 0.7121 | -5.96% | $88.66M | vs EQ |
| ICCCImmuCell Corporation | 9.75 | +0.62% | $88.55M | vs EQ |
| CNXUConexeu Sciences Inc. | 3.45 | -5.22% | $97.31M | vs EQ |
| CGTXCognition Therapeutics Inc. | 0.8952 | -4.42% | $85.13M | vs EQ |
Indexes, lists and sector
Appears in lists
Equillium stock FAQ
What is Equillium's stock price today?
EQ last traded at $1.44 as of Oct 8, 4:00 PM EDT, up 3.60% on the day. Prices are delayed at least 15 minutes.
When is Equillium's next earnings date?
Equillium is expected to report earnings on Thursday, November 12, 2026.
Who is Equillium's CEO?
Mr. Bruce Steel is the chief executive officer of Equillium Inc., which has about 14 employees.
What is the EQ 52-week high?
The 52-week high for EQ is $3.54 and the 52-week low is $0.76. The stock is currently 59.3% below its high.